We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00665613
First Posted: April 24, 2008
Last Update Posted: October 14, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Staten Island University Hospital
Information provided by (Responsible Party):
Mario Castellanos, North Shore Long Island Jewish Health System
April 22, 2008
April 24, 2008
October 14, 2015
October 2004
March 2009   (Final data collection date for primary outcome measure)
Bone Density [ Time Frame: 5 to 10 years ]
bone density as measured by xray to assess bone strength nd risk of fracture
Not Provided
Complete list of historical versions of study NCT00665613 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin
The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin
The purpose of this study is to determine if osteoporosis is an unrecognized complication of chronic anticoagulation with warfarin.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
patients on warfarintherapy in the SIUH coumadin center
Osteoporosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
March 2009
March 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients on warfarin that have had BMD within a year

Exclusion Criteria:

  • Patients on bisphosphates, SERMS, anticonvulsants, estrogens, androgens, calcitonin, hctz and thyroid hormone replacement
Sexes Eligible for Study: All
18 Years to 100 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00665613
04-054
Yes
Not Provided
Not Provided
Mario Castellanos, North Shore Long Island Jewish Health System
Northwell Health
Staten Island University Hospital
Not Provided
Northwell Health
October 2015